[Antihypertensive drugs in clinical development].
Kikkawa
Kohei
K
kohei-k@tanabe.co.jp
D000577:Amides; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology*; D000077545:Eplerenone; D005650:Fumarates / Q000494:pharmacology; D006575:Heterocyclic Compounds, 3-Ring / Q000494:pharmacology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone / Q000031:analogs & derivatives / Q000494:pharmacology
C479877:AVE 7688; D000577:Amides; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000959:Antihypertensive Agents; D005650:Fumarates; D006575:Heterocyclic Compounds, 3-Ring; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; C446481:aliskiren; D000077545:Eplerenone